Conversion of atrial flutter in pediatric patients by transesophageal atrial pacing: a safe, effective, minimally invasive procedure.

Conversion of atrial flutter in pediatric patients by transesophageal atrial pacing: a safe, effective, minimally invasive procedure.
复制标题

通过经食管心房起搏治疗儿科患者的心房扑动:一种安全、有效、微创的手术。

DOI:
10.1016/0002-8703(95)90448-4
复制
发表时间:
1995
影响因子:
4.8
通讯作者:
Saul,JP
Saul,JP
中科院分区:
医学2区
文献类型:
--
作者:
Rhodes,LA;Walsh,EP;Saul,JP

文献摘要

被引文献

相似文献

房性折返性心动过速,通常被称为心房扑动,是一种在普通儿科人群中不常见的心律失常,但在先天性心脏病患者中常见。治疗心律失常的一个目标是终止心律失常,使心房恢复其潜在的节奏。本文报告了102例(158次)儿童患者使用经食道心房调搏终止心房折返性心动过速。患者年龄从1小时到41.5岁不等。在158集中,112集(71%)转化成功。在最初的起搏尝试导致心房颤动后,112次发作中有6次需要输注普鲁卡因胺。在比较成功和不成功的转归方面,患者的年龄或心动过速持续时间之间没有显著差异。相反,成功转复的心动过速患者的心房周期长度明显大于未成功转复的患者。经食道心房调搏是终止儿童心房扑动的一种安全有效的方法。它是微创的,通常可以在门诊进行,偶尔可以通过静脉注射普鲁卡因胺来促进这项技术的实施。
Atrial reentry tachycardia, often termed atrial flutter, is an arrhythmia that is uncommon in the general pediatric population but is seen frequently in patients with congenital heart disease. One goal in treating the arrhythmia is to terminate it, returning the atrium to its underlying rhythm. This report describes the use of transesophageal atrial pacing to attempt termination of atrial reentry in 102 pediatric patients (158 episodes). The patients ranged in age from 1 hour to 41.5 years. Conversion was successful for 112 (71%) of 158 episodes. Six of the 112 episodes required an infusion of procainamide after initial attempts at pacing led to atrial fibrillation. There were no significant differences between the ages of patients or the duration of the tachycardia in comparing successful versus unsuccessful conversions. In contrast, the atrial cycle lengths for the successfully converted tachycardias were significantly greater than for unsuccessful attempts. Transesophageal atrial pacing is a safe and effective means of terminating atrial flutter in the pediatric population. It is minimally invasive, it can often be performed in an outpatient setting, and the technique may occasionally be facilitated by infusion of intravenous procainamide.